A Phase 3 interventional study of Pemetrexed and Cetuximab in Non Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 67 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-10-15.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 33 under way, 12 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.
Among the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by enrollment of the 224 interventional ones that give a count, is one of 20 that started in 2005, is one of 45 in phase 3, and was the 8th registered.
7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →22 of the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
Guangzhou Medical University · Sites in China
Ages 18–75
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–85
Shanghai Chest Hospital · Sites in China
Ages 18+
Taipei Veterans General Hospital, Taiwan · Sites in Taiwan
Ages 20+
By country, each count listing its studies:
Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
228 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 148 · Phase 3 48 · Phase 4 8
First in 2001; this study’s year is marked. 20 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 939 is above the median of 62 across 6,031 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 65 across the 224 interventional studies. Of the 161 that completed or were terminated, 89 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 228 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 5th largest by enrollment of the 139 interventional ones that give a count, is one of 10 that started in 2005, is one of 25 in phase 3, and was the 12th registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
7 of the studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
| NCT05805631Taipei Veterans General Hospital, TaiwanIntrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC | 2026-12-31 |
| NCT06440954Hunan Province Tumor HospitalEfficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This trial is a multicenter, open-label, randomized, Phase III study in patients with recurrent or progressive Non-Small Cell Lung Cancer (NSCLC) after failure of an initial platinum-based chemotherapy. Patients will receive either Docetaxel or Pemetrexed as chemotherapy at the investigator's choice. Within each chemotherapy group, patients will be randomized to receive Cetuximab plus chemotherapy or chemotherapy alone (Cetuximab \& Pemetrexed or Pemetrexed alone; Cetuximab \& Docetaxel or Docetaxel alone).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pemetrexed · Biological: Cetuximab
Drug: Pemetrexed
Biological: Cetuximab · Drug: Docetaxel
Drug: Docetaxel
Pemetrexed 500 mg/m\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.
Also known as: Alimta, LY231514
Cetuximab 400/250 mg/m\^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity.
Also known as: Erbitux, LY2939777
Docetaxel 75 mg/m\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.
Progression Free Survival (PFS)
PFS was defined as the time from randomization until the date of progressive disease (PD) or death from any cause. Participants who were alive and without progression were censored at the date of their last tumor assessment. PFS was assessed by the independent review committee (IRC) in the Pemetrexed group (Cetuximab \& Pemetrexed versus Pemetrexed) and by the investigator in the Docetaxel group (Cetuximab \& Docetaxel versus Docetaxel).
Time frame: Randomization to progression of disease or death due to any cause up to 59.6 months
Overall Survival (OS)
OS was defined as the time from randomization to death. Participants without a date of death were censored on the last date participants were known to be alive, or lost to follow-up.
Time frame: Randomization to the date of death from any cause up to 72.8 months
Proportion of Randomized Participants With the Best Overall Response (OR) of Partial Response (PR) or Complete Response (CR) (Overall Response Rate [ORR])
The best overall response rate (ORR) was the proportion of randomized participants with a best OR of CR or PR, according to modified World Health Organization (WHO) guidelines. It was calculated as the total number of participants with CR or PR divided by the total number of participants treated in that arm. Participants with no post-baseline evaluation were considered as non-responders. The tumor response was assessed by the independent review committee (IRC) in the Pemetrexed group and by the investigator in the Docetaxel group.
Time frame: Randomization until progression of disease or death from any cause up to 59.6 months
Proportion of Randomized Participants With Best Overall Response (OR) of Partial Response (PR), Complete Response (CR), or Stable Disease (SD)
The disease control rate (DCR) was the proportion of randomized participants with a best OR of CR, PR or SD according to modified World Health Organization (WHO) guidelines. It was calculated as the total number of participants with CR, PR or SD divided by the total number of participants randomized in that arm. The tumor response was assessed by the independent review committee (IRC) in the Pemetrexed group and by the investigator in the Docetaxel group.
Time frame: Randomization to progression of disease or death due to any cause up to 59.6 months
Percentage of Participants With Symptomatic Response (Symptom Response Rates) Using the Lung Cancer Subscale (LCS) Scores of Functional Assessment of Cancer Therapy for Participants With Lung Cancer (FACT-L)
The FACT-LCS is a set of 7 questions to inventory problems specific to lung cancer symptoms. Participants rate each item on a 5-point Likert-type scale from 0 (not at all) to 4 (very much). Scores range from 0-28 and higher score indicates fewer symptoms. Symptom response (improvement) was defined as ≥2 point increase from baseline in the 7-item LCS score that was maintained for 2 consecutive assessments at least 3 weeks, and not \>5 weeks apart for participants, whose baseline LCS score was ≤26. Symptom response rate was the percentage of participants with symptomatic response.
Time frame: At baseline, every 3 weeks and 30 days after end of therapy up to 50 months
Time to Symptomatic Progression
The FACT-LCS (see description in Outcome measure 5) inventories problems specific to lung cancer symptoms. Using this Scale, Symptom progression = a ≥ 2 point decrease from baseline in LCS score maintained for 2 consecutive assessments ≥3 weeks, and \<5 weeks, apart. The symptom progression date = the first of 2 consecutive assessments with a ≥2 point decline. Time to symptomatic progression = the time from randomization to the symptom progression date. For participants with no symptom progression, time to symptomatic progression was censored the date of last symptom assessment.
Time frame: Randomization until symptomatic progression up to 48.3 months
Duration of Overall Response (OR)
The duration of response, in participants with best OR of complete response (CR) or partial response (PR), was measured from the date criteria are met for CR/PR (not confirmation date, whichever was first recorded), until the first occurrence date that the criteria of progressive disease (PD) was met, or death. Participants who were alive and without progression were censored at the date of their last independent review committee (IRC) tumor assessment. The tumor response and progression were assessed by the IRC in the Pemetrexed group and by the investigator in the Docetaxel group.
Time frame: Time of first occurrence of either (PR) or (CR) to the first date of progressive disease or death up to 32.5 months
Number of Participants With Common Toxicity Criteria (CTC) Grade 3 or 4 Toxicities
National Cancer Institutes-Common Toxicity Criteria version 3.0 was used by investigators to assess participant toxicities. Mapping of investigator verbatim terms to CTCAE terms was done by the sponsor/designee using CTCAE v4.0. Participants reported had grade 3 or 4 toxicities (or both potentially). Grade 3 AEs: severe or medically significant but not immediately life-threatening;hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4 AEs: life-threatening consequences; urgent intervention indicated.
Time frame: Time from first dose to 30 days after last dose of study therapy up to 28.3 months for Cetuximab & Pemetrexed (versus Pemetrexed alone) and up to 54.3 months for Cetuximab + Docetaxel (versus Docetaxel alone)
| Milestone | Cetuximab & Pemetrexed | Pemetrexed | Cetuximab and Docetaxel | Docetaxel |
|---|---|---|---|---|
| Started | 302 | 304 | 167 | 166 |
| Completed | 6 | 62 | 7 | 23 |
| Not completed | 296 | 242 | 160 | 143 |
| Withdrew: Adverse event | 40 | 22 | 26 | 11 |
| Withdrew: Progressive disease | 213 | 179 | 105 | 98 |
| Withdrew: Death | 10 | 6 | 11 | 9 |
| Withdrew: Withdrawal by subject | 21 | 16 | 13 | 22 |
| Withdrew: Protocol violation | 4 | 4 | 2 | 0 |
| Withdrew: Liver function test results elevated | 0 | 0 | 1 | 1 |
| Withdrew: Surgery needed could not start in 7 days | 0 | 0 | 1 | 0 |
| Withdrew: Physician decision | 5 | 6 | 1 | 1 |
| Withdrew: Not eligible | 1 | 7 | 0 | 1 |
| Withdrew: Started palliative radiotherapy | 1 | 0 | 0 | 0 |
| Withdrew: Started radiotherapy regimen | 0 | 1 | 0 | 0 |
| Withdrew: Primary tumor removed in other surgery | 0 | 1 | 0 | 0 |
| Withdrew: Data inadvertently lost by site | 1 | 0 | 0 | 0 |
PFS was defined as the time from randomization until the date of progressive disease (PD) or death from any cause. Participants who were alive and without progression were censored at the date of their last tumor assessment. PFS was assessed by the independent review committee (IRC) in the Pemetrexed group (Cetuximab \& Pemetrexed versus Pemetrexed) and by the investigator in the Docetaxel group (Cetuximab \& Docetaxel versus Docetaxel).
| months | Cetuximab & Pemetrexed | Pemetrexed | Cetuximab & Docetaxel | Docetaxel |
|---|---|---|---|---|
| Progression Free Survival (PFS) | 2.89 (2.69 to 3.22) | 2.76 (2.53 to 3.29) | 2.37 (1.61 to 2.89) | 1.54 (1.45 to 2.50) |
OS was defined as the time from randomization to death. Participants without a date of death were censored on the last date participants were known to be alive, or lost to follow-up.
| months | Cetuximab & Pemetrexed | Pemetrexed | Cetuximab & Docetaxel | Docetaxel |
|---|---|---|---|---|
| Overall Survival (OS) | 6.93 (6.28 to 7.85) | 7.79 (6.77 to 8.41) | 5.75 (4.73 to 8.31) | 8.15 (6.11 to 9.20) |
The best overall response rate (ORR) was the proportion of randomized participants with a best OR of CR or PR, according to modified World Health Organization (WHO) guidelines. It was calculated as the total number of participants with CR or PR divided by the total number of participants treated in that arm. Participants with no post-baseline evaluation were considered as non-responders. The tumor response was assessed by the independent review committee (IRC) in the Pemetrexed group and by the investigator in the Docetaxel group.
| proportion of participants | Cetuximab & Pemetrexed | Pemetrexed | Cetuximab & Docetaxel | Docetaxel |
|---|---|---|---|---|
| Proportion of Randomized Participants With the Best Overall Response (OR) of Partial Response (PR) or Complete Response (CR) (Overall Response Rate [ORR]) | 0.066 (0.038 to 0.095) | 0.043 (0.020 to 0.066) | 0.078 (0.037 to 0.118) | 0.066 (0.028 to 0.104) |
The disease control rate (DCR) was the proportion of randomized participants with a best OR of CR, PR or SD according to modified World Health Organization (WHO) guidelines. It was calculated as the total number of participants with CR, PR or SD divided by the total number of participants randomized in that arm. The tumor response was assessed by the independent review committee (IRC) in the Pemetrexed group and by the investigator in the Docetaxel group.
| proportion of participants | Cetuximab & Pemetrexed | Pemetrexed | Cetuximab & Docetaxel | Docetaxel |
|---|---|---|---|---|
| Proportion of Randomized Participants With Best Overall Response (OR) of Partial Response (PR), Complete Response (CR), or Stable Disease (SD) | 0.522 (0.465 to 0.578) | 0.480 (0.424 to 0.536) | 0.335 (0.264 to 0.407) | 0.253 (0.187 to 0.319) |
The FACT-LCS is a set of 7 questions to inventory problems specific to lung cancer symptoms. Participants rate each item on a 5-point Likert-type scale from 0 (not at all) to 4 (very much). Scores range from 0-28 and higher score indicates fewer symptoms. Symptom response (improvement) was defined as ≥2 point increase from baseline in the 7-item LCS score that was maintained for 2 consecutive assessments at least 3 weeks, and not \>5 weeks apart for participants, whose baseline LCS score was ≤26. Symptom response rate was the percentage of participants with symptomatic response.
| percentage of participants | Cetuximab & Pemetrexed | Pemetrexed | Cetuximab & Docetaxel | Docetaxel |
|---|---|---|---|---|
| Percentage of Participants With Symptomatic Response (Symptom Response Rates) Using the Lung Cancer Subscale (LCS) Scores of Functional Assessment of Cancer Therapy for Participants With Lung Cancer (FACT-L) | 17.1 (12.7 to 21.6) | 22.9 (17.9 to 27.8) | 17.3 (11.3 to 23.4) | 13.5 (8.2 to 18.9) |
The FACT-LCS (see description in Outcome measure 5) inventories problems specific to lung cancer symptoms. Using this Scale, Symptom progression = a ≥ 2 point decrease from baseline in LCS score maintained for 2 consecutive assessments ≥3 weeks, and \<5 weeks, apart. The symptom progression date = the first of 2 consecutive assessments with a ≥2 point decline. Time to symptomatic progression = the time from randomization to the symptom progression date. For participants with no symptom progression, time to symptomatic progression was censored the date of last symptom assessment.
| months | Cetuximab & Pemetrexed | Pemetrexed | Cetuximab & Docetaxel | Docetaxel |
|---|---|---|---|---|
| Time to Symptomatic Progression | NA (NA to NA) | NA (NA to NA) | NA (7.00 to NA) | NA (NA to NA) |
The duration of response, in participants with best OR of complete response (CR) or partial response (PR), was measured from the date criteria are met for CR/PR (not confirmation date, whichever was first recorded), until the first occurrence date that the criteria of progressive disease (PD) was met, or death. Participants who were alive and without progression were censored at the date of their last independent review committee (IRC) tumor assessment. The tumor response and progression were assessed by the IRC in the Pemetrexed group and by the investigator in the Docetaxel group.
| months | Cetuximab & Pemetrexed | Pemetrexed | Cetuximab & Docetaxel | Docetaxel |
|---|---|---|---|---|
| Duration of Overall Response (OR) | 4.17 (2.92 to 5.45) | 6.93 (3.98 to 16.36) | 5.36 (2.73 to 6.93) | 5.39 (3.12 to 7.16) |
National Cancer Institutes-Common Toxicity Criteria version 3.0 was used by investigators to assess participant toxicities. Mapping of investigator verbatim terms to CTCAE terms was done by the sponsor/designee using CTCAE v4.0. Participants reported had grade 3 or 4 toxicities (or both potentially). Grade 3 AEs: severe or medically significant but not immediately life-threatening;hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4 AEs: life-threatening consequences; urgent intervention indicated.
| participants | Cetuximab & Pemetrexed | Pemetrexed | Cetuximab + Docetaxel | Docetaxel |
|---|---|---|---|---|
| Number of Participants With Common Toxicity Criteria (CTC) Grade 3 or 4 Toxicities | 179 | 143 | 112 | 97 |
Collected over Randomization to 30 days after study therapy up to 72.8 months for Cetuximab & Pemetrexed (versus just Pemetrexed) and up to 64.3 months for Cetuximab + Docetaxel (versus just Docetaxel). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cetuximab & Pemetrexed | — | 119/292 (40.8%) | 289/292 (99%) |
| Pemetrexed | — | 86/289 (29.8%) | 281/289 (97.2%) |
| Cetuximab and Docetaxel | — | 84/159 (52.8%) | 159/159 (100%) |
| Docetaxel | — | 60/149 (40.3%) | 147/149 (98.7%) |
| Event | Cetuximab & Pemetrexed | Pemetrexed | Cetuximab and Docetaxel | Docetaxel |
|---|---|---|---|---|
| DehydrationMetabolism and nutrition disorders | 11/292 | 6/289 | 17/159 | 4/149 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/292 | 4/289 | 13/159 | 11/149 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 14/292 | 11/289 | 12/159 | 6/149 |
| PneumoniaInfections and infestations | 16/292 | 17/289 | 9/159 | 10/149 |
| NeutropeniaBlood and lymphatic system disorders | 4/292 | 4/289 | 10/159 | 3/149 |
| PyrexiaGeneral disorders | 7/292 | 5/289 | 10/159 | 3/149 |
| Deep vein thrombosisVascular disorders | 5/292 | 0/289 | 8/159 | 2/149 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 9/292 | 3/289 | 4/159 | 7/149 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 1/292 | 2/289 | 7/159 | 3/149 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 7/292 | 2/289 | 7/159 | 3/149 |
| Event | Cetuximab & Pemetrexed | Pemetrexed | Cetuximab and Docetaxel | Docetaxel |
|---|---|---|---|---|
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 223/292 | 5/289 | 100/159 | 4/149 |
| FatigueGeneral disorders | 158/292 | 133/289 | 88/159 | 74/149 |
| NeutropeniaBlood and lymphatic system disorders | 32/292 | 32/289 | 74/159 | 46/149 |
| DiarrhoeaGastrointestinal disorders | 81/292 | 36/289 | 63/159 | 22/149 |
| NauseaGastrointestinal disorders | 112/292 | 89/289 | 53/159 | 38/149 |
| Decreased appetiteMetabolism and nutrition disorders | 86/292 | 58/289 | 54/159 | 45/149 |
| StomatitisGastrointestinal disorders | 54/292 | 21/289 | 53/159 | 23/149 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 66/292 | 60/289 | 43/159 | 38/149 |
| ConstipationGastrointestinal disorders | 75/292 | 60/289 | 41/159 | 25/149 |
| AnaemiaBlood and lymphatic system disorders | 70/292 | 64/289 | 40/159 | 35/149 |
| Age Continuous(years) | Cetuximab & Pemetrexed | Pemetrexed | Cetuximab & Docetaxel | Docetaxel | Total |
|---|---|---|---|---|---|
| Mean | 62.8 ± 10.0 | 64.0 ± 9.4 | 63.6 ± 9.4 | 63.9 ± 9.2 | 63.5 ± 9.5 |
| Sex: Female, Male(Participants) | Cetuximab & Pemetrexed | Pemetrexed | Cetuximab & Docetaxel | Docetaxel | Total |
|---|---|---|---|---|---|
| Female | 128 | 116 | 75 | 73 | 392 |
| Male | 173 | 188 | 92 | 93 | 546 |
| Race/Ethnicity, Customized(participants) | Cetuximab & Pemetrexed | Pemetrexed | Cetuximab & Docetaxel | Docetaxel | Total |
|---|---|---|---|---|---|
| White | 268 | 265 | 146 | 141 | 820 |
| Black or African American | 25 | 24 | 13 | 20 | 82 |
| Asian | 3 | 6 | 5 | 2 | 16 |
| Hispanic | 4 | 8 | 2 | 2 | 16 |
| Unknown or Not Reported | 1 | 1 | 1 | 1 | 4 |
| Region of Enrollment(participants) | Cetuximab & Pemetrexed | Pemetrexed | Cetuximab & Docetaxel | Docetaxel | Total |
|---|---|---|---|---|---|
| United States | 265 | 270 | 152 | 151 | 838 |
| Canada | 36 | 34 | 15 | 15 | 100 |
| Epidermal growth factor receptor (EGFR) by immunohistochemistry(participants) | Cetuximab & Pemetrexed | Pemetrexed | Cetuximab & Docetaxel | Docetaxel | Total |
|---|---|---|---|---|---|
| +1 | 36 | 35 | 13 | 19 | 103 |
| +2 | 46 | 53 | 26 | 34 | 159 |
| +3 | 118 | 108 | 72 | 58 | 356 |
| 0 | 21 | 32 | 12 | 10 | 75 |
| Missing | 80 | 76 | 44 | 45 | 245 |
| Karnofsky Performance Status(participants) | Cetuximab & Pemetrexed | Pemetrexed | Cetuximab & Docetaxel | Docetaxel | Total |
|---|---|---|---|---|---|
| 60 | 12 | 14 | 2 | 11 | 39 |
| 70 | 35 | 35 | 21 | 14 | 105 |
| 80 | 103 | 91 | 55 | 57 | 306 |
| 90 | 101 | 116 | 74 | 64 | 355 |
| 100 | 48 | 47 | 14 | 18 | 127 |
| Missing/unknown | 2 | 1 | 1 | 2 | 6 |
| Pathological Diagnosis(participants) | Cetuximab & Pemetrexed | Pemetrexed | Cetuximab & Docetaxel | Docetaxel | Total |
|---|---|---|---|---|---|
| Adenocarcinoma | 161 | 185 | 99 | 83 | 528 |
| Large cell carcinoma | 19 | 7 | 7 | 3 | 36 |
| All other non-squamous diagnoses | 45 | 41 | 20 | 29 | 135 |
| Squamous cell carcinoma | 76 | 71 | 41 | 51 | 239 |
The record gives a start of Jan 2005, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2012, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pemetrexed · Cetuximab · Docetaxel
Carcinoma, Non-Small-Cell Lung →